2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1319

Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis
Abstract Number: 1320

Individual Socio-economic Status and Symptomatic Hip and Knee Osteoarthritis: A Longitudinal Study, Results from the KHOALA Cohort
Abstract Number: 1321

What Is the Relationship Between the 3 Knee Bones in Osteoarthritis? Baseline and Longitudinal Associations Using a Latent Growth Modelling Approach on 37,583 MR Images from the Osteoarthritis Initiative
Abstract Number: 1322

Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain
Abstract Number: 1323

Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma
Abstract Number: 1324

Visceral Fat Deposition Associated with Pain in Osteoarthritis
Abstract Number: 1325

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA
Abstract Number: 1326

Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
Abstract Number: 1327

The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Abstract Number: 1328

The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis
Abstract Number: 1329

Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Abstract Number: 1330

No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years
Abstract Number: 1331

No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab
Abstract Number: 1332

United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Abstract Number: 1333

The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].